# RESULTS as of March 31, 2023

Monday, APRIL 24, 2023




Desirable places to live



#### **DISCLAIMER**





Distribution of this document may be restricted in certain countries by legislation or regulations. As a result, any person who comes into possession of this document should familiarise themselves and comply with such restrictions. To the extent permitted by applicable law, Icade excludes all liability and makes no representation regarding the violation of any such restrictions by any person.



# **AGENDA**

- 1 Q1 2023 Key takeaways
- **2** Performance of Business Lines
- 3 Icade Santé's liquidity
- 4 Say on Climate & Biodiversity
- 5 2023 Outlook





<u>1</u>.

Q1 2023 Key takeaways

# Q1 2023 - KEY TAKEAWAYS



# Resilient operational indicators, reflecting solid fundamentals in a challenging market Total group share revenue stands at €300m

Exclusivity agreement between Icade and Primonial REIM for the sale of Icade Santé

A potential transaction of €3bn in the healthcare market

Significant deleveraging expected by the end of 2023 Confirmation by S&P of the Icade's rating BBB+, stable outlook

## AGM held on April 21, 2023

- Approval of 2022 dividend at €4.33 per share fully paid in cash
- Approval of Say on Climate & Biodiversity resolution (for the second year in a row) by more than 98%





## **REVENUE AS OF MARCH 31, 2023 AT c.€300M IN GROUP SHARE**

- Strong revenue from office investment division, in a context of significant disposals in 2022; positive impact of indexation
- Significant slowdown of the residential market, seasonality impact in Q1 for Icade Promotion

(in €m)	03/31/2023	03/31/2022 restated	Chg. 2023 vs. 2022 (%)	LFL chg. 2023 vs. 2022 (%)
Gross rental income from Office Property Investment – Group Share	83.3	85.7	(2.8)%	2.8%
Other income <sup>(1)</sup>	4.7	5.5	(13.5%)	(9.0)%
Property Development revenue – Group Share	202.3	240.8	(16)%	(20.7)%
Other revenue <sup>(2)</sup>	6.3	5.7	9.8%	9.8%
CONSOLIDATED REVENUE – Group Share	296.6	337.7	(12.2)%	(14.4)%
CONSOLIDATED REVENUE – IFRS	286.7	324.5	(11.7)%	(14.9)%

Application of IFRS 5 in anticipation of the full deconsolidation of the Healthcare business (as of the closing of the first stage)



The Group's revenues for Q1 2023 do not include the contribution of the Healthcare business, with restatement of the comparable period





<u>2</u>.

# Performance of Business Lines



# **OFFICE PROPERTY INVESTMENT – Q1 2023 KEY HIGHLIGHTS**

### Solid leasing activity in a quiet market

c.60,000 sq.m

Total floor area of leases signed or renewed in Q1 2023

6 years

**WALB** related to leases signed or renewed since January 1

Securing €14m

in annual rental income

**Asset rotation** 

c.€150m

Under preliminary agreement incl. 2 mature assets – fully let (average office yield: 4.0%)

Incl. **45,000 sq.m** in renewals

Adecco (Lyon) 13,300 sq.m 9 years



Système U
(Parc Paris Orly-Rungis)
21,000 sq.m
9 years



Incl. **14,000 sq.m** of new signatures

**Parc Paris Orly-Rungis** 

c.5,000 sq.m incl. Vinci Energies for 3 000 sq.m, 9 years



Equinix (datacenter)
Parc des Portes de Paris
c.7,500 sq.m
9 years



GRAND CENTRAL
Marseille, 1st district
8,500 sq.m



EKO ACTIVE
Marseille, 2<sup>nd</sup> district
8,200 sq.m



Solid GRI including significant disposals, positive impact of indexation

€83.3m

GRI in group share - +2.8%: LFL change in Q1 2023

+3.7%

Excluding impact of 2022 disposals

c.+5%

Indexation effect on rents in Q1 2023 - 100% leases indexed



- A solid start to the year for the leasing activity
- Opportunistic approach on asset rotation, both disposals and investment

# **PROPERTY DEVELOPMENT – Q1 2023 KEY HIGHLIGHTS**



### A market slowdown impacting operating indicators

Economic Revenue €227m

-14% vs. O1 2022

**Housing Orders** 

€175m

-15% for individual investors

These numbers come after a very strong 2022 year

(+17% in 2022 economic revenue)

### **Emblematic projects**

Icade Promotion chosen to codevelop the Gavy site in Saint Nazaire

Successful launch of the "58 Victor Hugo"





Mixed use project 340 new homes for every needs



Conversion of a hotel into 166 residential housing units in Neuilly-sur-Seine

### Icade Promotion is agile and adapts

- Increased attention on the evolution of stocks
- Reinforced monitoring of commercial launches prices adjustments and commercial offers
- **3** Renegotiation of land plots
- 4 Adjustment of structural costs

## **Resilient leading indicators**

€1.8bn

A solid backlog enabling Icade to absorb 2023 market decline







<u>3</u>.

**Icade Santé's liquidity** 

# ICADE AND PRIMONIAL REIM SIGN AN EXCLUSIVITY AGREEMENT FOR THE ACQUISITION OF ICADE'S STAKE IN ICADE SANTÉ



March 13, 2023: Exclusivity agreement between Icade, Icade Santé's minority shareholders and Primonial for (i) the acquisition of Icade's stake in Icade Santé (58%) and (ii) the sale of the asset portfolio owned by Icade Healthcare Europe (IHE)

#### **Financial stakes for Icade**

€2.6bn(1)

value of the **investments** in the two entities:

**Icade Santé**: €2.3bn

**IHE**: €0.3bn

€0.4bn

in shareholder loan repayments

# Structure of the proposed transaction

#### **Stage 1** (by July 2023 at the latest)<sup>(2)</sup>:


- Sale of 64%<sup>(3)</sup> of Icade's stake in Icade Santé for €1.4bn
- Repayment of Icade Santé's shareholder loan

#### **Stage 2** (June 2023–Dec. 2025):

 Acquisition of Icade's remaining stake in Icade Santé through the collection of funds managed by Primonial REIM and the entry of new interested investors

#### **Stage 3** (June–Dec. 2024):

- Sale of the IHE assets
- Repayment of IHE's shareholder loan



(1) EPRA NTA as of December 31, 2022 on a proportionate consolidation basis

(2) Subject to the signing of the final agreements once the process of informing and consulting Icade's representative bodies has been completed and the customary regulatory conditions precedent have been met.

These include confirmation by the AMF that the transaction will not give rise to a buyout offer with squeeze-out for Icade's share capital, pursuant to Article 236-6 of the AMF's general regulations

(3) After adjusting for the 2022 dividend





4.
Say on Climate & Biodiversity

# ICADE

#### SAY ON CLIMATE & BIODIVERSITY FOR THE SECOND YEAR IN A ROW: APPROVED BY MORE THAN 98% (98.3%)

# Low carbon strategy: reinforced medium-term ambitions 2022 results in line with the pathway

GHG emissions reduction targets by 90% in absolute terms between 2019 and 2050<sup>(1)</sup>

Icade's 1.5°C-aligned Net Zero Pathway approved by the SBTi in October 2022







Carbon reduction targets for 2019-2030<sup>(2)</sup>

OFFICE INVESTMENT

-60%

HEALTHCARE INVESTMENT

-35%

PROPERTY DEVELOPMENT

-41%

CORPORATE -30%

Carbon footprint results over the 2019-2022 period



# Biodiversity strategy: 2019-2022 results above targets!



**63%** of new builds in Property Development division in **net positive impact on Biodiversity** 

206,000 sq.m

restored and preserved ecosystems since 2016

#### Reinforced commitments by 2030

1

Rewilding 100% of the Property Development Division's new builds and the Office Property Investment Division's business parks by 2030

2

Nature-boosting solutions for 90% of the Office Property Investment Division's buildings

3

Voluntary measures to restore or preserve ecosystems through carefully selected projects





**5.** 2023 Outlook

# **CONFIRMATION OF THE 2023 GUIDANCE AND DIVIDEND POLICY**



# **Guidance announced** on February 20, 2023

# **Updated guidance**

2023 Group NCCF per share

# Stable to slightly up

Excluding impact of 2023 disposals



## **Unchanged**

NCCF to be confirmed in July 2023 according to the effective date of the transaction

2023 dividend policy In line with the change in NCCF 80% payout ratio



**Unchanged** 



Impact of special dividends to be confirmed in July 2023